This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
(Lopinavir + ritonavir) is under clinicaldevelopment by Douglas Pharmaceuticals and currently in Phase I for Genital Warts (Condylomata Acuminata). Douglas collaborates with scientific researchers and external medical experts to advance clinicalresearch. It operates in New Zealand, Fiji and the US.
(Lopinavir + ritonavir) is under clinicaldevelopment by Douglas Pharmaceuticals and currently in Phase I for Cervical Intraepithelial Neoplasia (CIN). Douglas collaborates with scientific researchers and external medical experts to advance clinicalresearch. It operates in New Zealand, Fiji and the US.
Merck has said it will abandon the KEYNOTE-991 study of PD-1 inhibitor Keytruda (pembrolizumab) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) after it showed no benefit on either overall survival (OS) or radiographic progression-free survival (rPFS) when the data was analysed midway though.
Among these, rare pediatric diseases present unique challenges and opportunities for rare disease drug development. Pediatric growth hormone deficiency (PGHD) is one such condition, affecting a child’s growth and development.
Amgens randomized, double-blind, placebo-controlled Phase II study enrolled 592 adults with obesity or overweight conditions, defined by a body mass index (BMI) of 30 or 27, respectively, with at least one obesity-related comorbidity.
For example, pediatric growth hormone deficiency (PGHD) affects approximately one in 3,500 to one in 10,000 children. Existing therapeutic options for PGHD consist of injectable formulations of recombinant human growth hormone (rhGH), administered subcutaneously either on a daily or weekly basis.
Amgen’s randomized, double-blind, placebo-controlled Phase II study enrolled 592 adults with obesity or overweight conditions, defined by a body mass index (BMI) of ≥30 or ≥27, respectively, with at least one obesity-related comorbidity.
Natriuretic peptides like N-terminal (NT)-pro hormone B type natriuretic peptide (NT-proBNP), or BNP, are routinely used for acute and chronic heart failure. Full-Service ClinicalDevelopment. Watch the recent webinar by Medpace on cardiac biomarkers in CV trials featuring Dr. Januzzi.
In the webinar, Dr. Shah was joined by her colleague Dr. Rujin Ju, MD, MSCR, FACOG, Medical Director of the Medical Department, Women’s Health at Medpace, who discussed innovation in women’s health clinicalresearch and FemTech — innovative technology-based products and services designed to address women’s health issues.
Priothera will use the funds to progress the clinicaldevelopment of mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, to enhance the curative potential of allogeneic hematopoietic stem cell transplantation (HSCT) for treating AML. Axol Bioscience – Based in the U.K.,
It is funded by the world’s leading charities dedicated to diabetes research, JDRF, and Diabetes UK, guided by both organizations’ strong commitment to facilitate deep interrogation of consolidated community-wide trial data as a means to accelerate clinicalresearch and therapeutic development for T1D.
Merck has the industry’s largest immuno-oncology clinicalresearch program. The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient’s likelihood of benefitting from treatment with KEYTRUDA, including exploring several different biomarkers.
“Triple-negative carcinoma grows and spreads faster than other sorts of carcinoma and consequently features a worse prognosis,” said Dr. Vicki Goodman, vice chairman , clinicalresearch, Merck Research Laboratories. Merck has the industry’s largest immuno-oncology clinicalresearch program.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content